BPC-157 and TB-500 are not FDA-approved
Cagrilintide and tirzepatide are discussed together because both are once-weekly injectables that reduce appetite and bodyweight, and both slow gastric emptying as part of that effect
While this may not be true for EACH and EVERY person, its still worth considering
This dual activityneuroprotection alongside growth promotionraised safety concerns during fosgonimeton clinical development
Spinocerebellar ataxia type 2 Spinocerebellar ataxia type 2a genetic neurodegenerative disorder due to a CAG repeat expansion mutation in the ATXN2 gene coding for the protein ataxin-2 63 has been associated to oxidative stress, in particular due to alterations in the enzymatic activity of antioxidant enzymes including GSTs 64
After repeated IM administration of BPC157 at 100 g/kg for seven consecutive days, the plasma concentration versus time curve (Figure 1C) and pharmacokinetic parameters (Table 3) were similar to those observed after a single IM injection at a dose of 100 g/kg, except for a slight increase in C max and AUC 0t
